The RareCyte® platform for next‐generation analysis of circulating tumor cells

Circulating tumor cells (CTCs) can reliably be identified in cancer patients and are associated with clinical outcome. Next‐generation “liquid biopsy” technologies will expand CTC diagnostic investigation to include phenotypic characterization and single‐cell molecular analysis. We describe here a r...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaldjian, Eric P., Ramirez, Arturo B., Sun, Yao, Campton, Daniel E., Werbin, Jeffrey L., Varshavskaya, Paulina, Quarre, Steven, George, Tad, Madan, Anup, Blau, C. Anthony, Seubert, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
CTC Technologies and Tools
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586054/
https://www.ncbi.nlm.nih.gov/pubmed/30277660
http://dx.doi.org/10.1002/cyto.a.23619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586054/
https://www.ncbi.nlm.nih.gov/pubmed/30277660
http://dx.doi.org/10.1002/cyto.a.23619

Ejemplares similares